Seagen, With Two Big Pharma Bidders, Nearly Lost Both
Executive Summary
Seagen was being pursued by another prospective big pharma buyer when it engaged Pfizer in merger negotiations, but both bidders walked away in late summer 2022; Pfizer returned in January.
You may also be interested in...
As Time Ticks, Industry Edges Closer To The Big Patent Cliff
Big pharma manufacturers are approaching a period that will be marked by the loss of exclusivity of many big-selling brands. All of the players are looking for ways to navigate the loss of revenues.
Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy
The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.
Biogen CEO Poses Million Dollar Question – Do We Need To Spend On Weight Loss Drugs?
As demand for Wegovy busts through capacity, Biogen’s Viehbacher asks if we need to spend on drugs for weight loss or other preventable diseases when the dollar could go towards non-preventable chronic diseases. Discussing investments at a recent conference, he was joined by Fidelity’s Rajiv Kaul who said the concept of therapeutic classes is outdated